Antitumor and antiangiogenic effects of aspirin-PC in ovarian cancer

Molecular Cancer Therapeutics

Volumn 15, Issue 12, 2016, Pages 2894-2904

  Huang, Yan ^a,b   Lichtenberger, Lenard M ^c   Taylor, Morgan ^a   Bottsford Miller, Justin N ^a   Haemmerle, Monika ^a   Wagner, Michael J ^a   Lyons, Yasmin ^a   Pradeep, Sunila ^a   Hu, Wei ^a   Previs, Rebecca A ^a   Hansen, Jean M ^a   Fang, Dexing ^c   Dorniak, Piotr L ^a   Filant, Justyna ^a   Dial, Elizabeth J ^c   Shen, Fangrong ^a   Hatakeyama, Hiroto ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPIRIN PHOSPHATIDYLCHOLINE; B 20; BEVACIZUMAB; CASPASE 3; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ASPIRIN-PHOSPHATIDYLCHOLINE; BIOLOGICAL MARKER; PHOSPHATIDYLCHOLINE; THROMBOXANE; THROMBOXANE B3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; TUMOR HYPOXIA; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HYPOXIA; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; BIOMARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOXIA; MICE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PHOSPHATIDYLCHOLINES; THROMBOXANES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85008312083     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0074     Document Type: Article

References (50)

1. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015;26:47-57.
2. Chan AT, Arber N, Burn J, Chia WK, Elwood P, HullMA, et al. Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res (Phila) 2012;5:164-78.
3. ThunMJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9:259-67.
4. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12.
5. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 2012;379: 1591-601.
6. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ. Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 2008;112:2289-300.
7. Davis AN, Afshar-Kharghan V, Sood AK. Platelet effects on ovarian cancer. Semin Oncol 2014;41:378-84.
8. Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, et al. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 2016; 126:1885-96.
9. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 2014; 106:djt431.
10. Baandrup L, Kjaer SK, Olsen JH, Dehlendorff C, Friis S. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol 2015; 26:787-92.
11. Ni X, Ma J, Zhao Y, Wang Y, Wang S. Meta-Analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. Br J Clin Pharmacol 2013;75:26-35.
12. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study. Br J Cancer 2014;111:623-7.
13. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: Bench to bedside. Gastroenterology 2008;135:41-60.
14. Lichtenberger LM. Role of phospholipids in protection of the GI mucosa. Dig Dis Sci 2013;58:891-3.
15. Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83.
16. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;1:154-8.
17. Lichtenberger LM, Zhou Y, Jayaraman V, Doyen JR, O'Neil RG, Dial EJ, et al. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: Characterization of interaction of NSAIDs with phosphatidylcholine. Biochim Biophys Acta 2012;1821:994-1002.
18. Lichtenberger LM, Barron M, Marathi U. Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity. Drugs Today (Barc) 2009;45:877-90.
19. Lichtenberger LM, Romero JJ, Dial EJ. Surface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirin. Br J Pharmacol 2007;150:913-9.
20. Lim YJ, Dial EJ, Lichtenberger LM. Advent of novel phosphatidylcholineassociated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety. Gut Liver 2013;7:7-15.
21. Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Lowdose aspirin-induced ulceration is attenuated by aspirin-phosphatidylcholine: A randomized clinical trial. Am J Gastroenterol 2011;106:272-7.
22. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM. Clinical trial: Comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment Pharmacol Ther 2008;28:431-42.
23. Dial EJ, Doyen JR, Lichtenberger LM. Phosphatidylcholine-Associated nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit DNA synthesis and the growth of colon cancer cells in vitro.Cancer Chemother Pharmacol 2006;57:295-300.
24. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013; 4:2427.
25. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood 2012;120: 4869-72.
26. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, et al. Combined anti-Angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 2009;8:2263-72.
27. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-8.
28. Huang J, HuW, Bottsford-Miller J, Liu T, Han HD, Zand B, et al. Cross-Talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib. Clin Cancer Res 2014;20:1846-55.
29. Tanaka N, Kato H, Inose T, Kimura H, Faried A, Sohda M, et al. Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2008;99:1468-75.
30. Lichtenberger LM, Romero JJ, de Ruijter WM, Behbod F, Darling R, Ashraf AQ, et al. Phosphatidylcholine association increases the anti-inflammatory and analgesic activity of ibuprofen in acute and chronic rodent models of joint inflammation: Relationship to alterations in bioavailability and cyclooxygenase-inhibitory potency. J Pharmacol Exp Ther 2001;298: 279-87.
31. Rupaimoole R, Wu SY, Pradeep S, Ivan C, Pecot CV, Gharpure KM, et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun 2014;5:5202.
32. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet Oncol 2009;10:501-7.
33. Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010;27:775-89.
34. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 1997;112:1000-16.
35. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
36. Lichtenberger LM, Ulloa C, Vanous AL, Romero JJ, Dial EJ, Illich PA, et al. Zwitterionic phospholipids enhance aspirin's therapeutic activity, as demonstrated in rodent model systems. J Pharmacol Exp Ther 1996;277:1221-7.
37. Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 2006;23:1489-98.
38. Usman MW, Luo F, Cheng H, Zhao JJ, Liu P. Chemopreventive effects of aspirin at a glance. Biochim Biophys Acta 2015;1855:254-63.
39. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539-41.
40. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 351:1709-11.
41. Mitchell JA, Warner TD. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006;5:75-86.
42. Cha YI, DuBois RN. NSAIDs and cancer prevention: Targets downstream of COX-2. Annu Rev Med 2007;58:239-52.
43. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-11.
44. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005;65:3735-44.
45. Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D, et al. Aspirin blocks EGF-stimulated cell viability in a COX-1 dependent manner in ovarian cancer cells. J Cancer 2013;4:671-8.
46. Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R, et al. Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats. Chem Biol Interact 2009;179:233-9.
47. Vane J. Towards a better aspirin. Nature 1994;367:215-6.
48. Vane JR. Inhibition of prostaglandin synthesis as amechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
49. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-Associated venous thrombosis. Blood 2013;122:1712-23.
50. Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) 2012;5:1346-71.